Dianthus Therapeutics (NASDAQ:DNTH) Earns Outperform Rating from Wedbush

by · The Cerbat Gem

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $46.00 price target on the stock. Wedbush’s target price points to a potential upside of 8.39% from the stock’s current price.

Other research analysts have also issued reports about the stock. Truist Financial initiated coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 14th. They set a “buy” rating and a $56.00 price target on the stock. Guggenheim lifted their price objective on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Raymond James Financial reiterated an “outperform” rating and set a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus lifted their price target on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $63.43.

Read Our Latest Stock Report on Dianthus Therapeutics

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $42.44 on Monday. The stock has a fifty day moving average price of $38.92 and a 200 day moving average price of $29.82. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $45.46. The company has a market cap of $1.82 billion, a PE ratio of -12.20 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. Analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 216,538 shares of company stock valued at $8,283,175. 16.56% of the stock is currently owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently bought and sold shares of the company. RA Capital Management L.P. raised its position in shares of Dianthus Therapeutics by 53.6% during the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock worth $52,003,000 after purchasing an additional 1,000,333 shares during the last quarter. Walleye Capital LLC lifted its position in Dianthus Therapeutics by 29.0% during the first quarter. Walleye Capital LLC now owns 106,931 shares of the company’s stock worth $1,940,000 after buying an additional 24,041 shares during the period. Nuveen LLC acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth approximately $1,168,000. Vestal Point Capital LP boosted its holdings in shares of Dianthus Therapeutics by 58.1% in the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock valued at $30,839,000 after purchasing an additional 625,069 shares during the last quarter. Finally, Sio Capital Management LLC boosted its holdings in Dianthus Therapeutics by 101.8% in the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after acquiring an additional 119,073 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Recommended Stories